Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
IQVIA HoldingsEli Lilly
Last price
$259.97$1,165.97
Currency
USD
USD
$43B$1.1T
32.4639.70
$8.08$29.79
1.170.50
0$6.69
00.59%
Sector
HealthHealth
Employees
94,00050,000
Ticker
$IQV$LLY
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $IQV or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.